NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$15.45 USD
-0.39 (-2.46%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $15.49 +0.04 (0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NAMS 15.45 -0.39(-2.46%)
Will NAMS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NAMS
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RBC Capital Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside